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ABSTRACT
Recent studies in experimental animals have shown that combining
antiangiogenic therapy with radiation can enhance tumor response.
Whether this enhancement is mainly attributable to angiogenesis inhibi-
tion, endothelial cell radiosensitivity, tumor cell apoptosis, or a decrease in
the number of hypoxic cells (improved oxygenation) is not known. We
designed this study to discern the role of tumor oxygenation. We chose an
anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody
(mAb) which has a known target, human VEGF. We also measured
interstitial fluid pressure (IFP) to test the hypothesis that the decreased
vascular permeability induced by the anti-VEGF mAb can lower IFP. The
effect of anti-VEGF mAb on vascular density, partial oxygen tension
(pO2), and apoptosis was also measured. Athymic NCr/Sed nu/nu mice
bearing 6-mm xenograft of the human glioblastoma multiforme (U87), or
colon adenocarcinoma (LS174T) were treated with anti-VEGF mAb in-
jected i.p. on alternate days for a total of six injections at a dosage of 100
mg/injection/mouse. For combined anti-VEGF and radiation, single radi-
ation doses were given under normal blood flow (20 and 30 Gy) or
clamped hypoxic conditions (30 and 40 Gy) 24 h after the sixth injection
of mAb. The inhibition of the growth of U87 and LS174T tumors by the
anti-VEGF mAb was associated with a significant reduction in tumor
vascular density and a relatively small increase in the number of apoptotic
cells. Compared with size-matched controls, IFP decreased by 74% in
LS174T, and 73% in U87 in mice treated with anti-VEGF mAb. After
antibody treatment pO2 increased significantly in U87, but did not change
in LS174T tumors. Combined treatment induced in U87 tumors a tumor-
growth delay (TGD) which was greater than additive; in LS174T except
for the 40-Gy hypoxic group, the effect was only additive. In both U87 and
LS174T the TGD induced by the antibody was independent of oxygen
levels in the tumor at the time of radiation. The fact that the increase in
TGD occurred under both normoxic and hypoxic conditions suggests that
anti-VEGF mAb treatment can compensate for the resistance to radiation
induced by hypoxia.
INTRODUCTION
Antiangiogenic agents can enhance the tumor response induced by
radiation (1–4). The inhibition of vessel formation is not the only
mechanism by which angiogenesis inhibitors delay tumor growth.
TNP-470, angiostatin, and anti-VEGF3 mAb can also increase tumor
cell apoptosis (5–8). Hypoxia, a major factor contributing to the
radioresistance of tumor cells, was reduced by angiogenesis inhibitors
(squalamine or the combination of TNP-470 and minocycline; 1, 9).
The combination of radiation with TNP-470 and minocycline induced
a greater TGD than radiation alone (1). Recent studies have shown
that angiostatin or anti-VEGF mAb radiosensitizes endothelial cells,
and the combination of radiation with the anti-VEGF antibody or
angiostatin increases the antitumor effects of radiation (2, 4). Thus,
antiangiogenic agents enhance the effects of radiation via both direct
and indirect mechanisms that target tumor and endothelial cells.
VEGF is a critical growth factor that promotes endothelial cell
proliferation, angiogenesis, and tumor growth, and maintains the
elevated vascular permeability of tumor vessels (10–12). Pre-clinical
studies have demonstrated that the growth of several tumor types is
inhibited by blocking antibodies against human VEGF (13–16). Both
the neutralization of VEGF action and the suppression of VEGF
expression are associated with increases in the fraction of apoptotic
tumor cells and reductions in vascular density and permeability (8, 11,
17). Grunstein et. al. (11) have recently shown that deletion of the
VEGF gene in ras-transformed fibroblasts increased tumor hypoxia as
measured by the formation of cellular adducts with the small molecule
nitroimidazole EF5.
We designed the present study to determine whether tumor growth
inhibition by the combination of radiation and anti-VEGF mAb is
dependent on tumor oxygen levels. To discern the role of tumor
oxygenation, treatment over 11 days with human anti-VEGF mAb
was followed by a single dose of ionizing radiation that was given
either under normoxic or clamped hypoxic conditions. To identify
other mechanisms that could inhibit tumor growth induced by the
antibody or the combination of antibody and radiation, the effects of
anti-VEGF mAb on pO2, vascular density, and the fraction of apo-
ptotic cells were measured.
Tumor interstitial hypertension is a likely cause of the poor delivery
of large therapeutic molecules to solid tumors (18). The high vascular
permeability and vascular resistance are two mechanisms that con-
tribute to the elevated IFP of solid tumors. VEGF increases vascular
permeability (12) and the anti-VEGF mAb decreases vascular perme-
ability (17). We, thus, tested the hypothesis that VEGF inhibition with
anti-VEGF mAb would lower tumor IFP.
MATERIALS AND METHODS
Animal Studies. Athymic NCr/Sed nude (nu/nu) mice, male, 8–10 weeks
old, from our defined flora- and specific pathogen-free animal colony were
used. The mice were further immunosuppressed 24 h before tumor transplan-
tation by whole-body irradiation with 5 Gy using a Gammacell 137Cs unit (0.8
Gy/min). Tumor chunks of the human glioblastoma U87 and colon adenocar-
cinoma LS174T were implanted s.c. in the legs of mice.
Anti-VEGF mAb. The murine antihuman VEGF mAb A.4.6.1. (anti-
VEGF mAb; Genentech, South San Francisco, CA) was used. Mice bearing
6-mm diameter tumors (100 mm3) were given six i.p. injections (one every
other day) of anti-VEGF mAb (100 mg/mouse) diluted in saline. Control
animals were injected with saline.
Irradiation Procedures. A single radiation dose under normal blood flow
(20 Gy, 30 Gy) or hypoxic (30 Gy, 40 Gy) conditions was administered at a
rate of about 5.6 Gy/min using a specially designed cesium irradiator. During
irradiation the mice were immobilized using a plastic tube fixed on a brass
plate, and the tumor was centered within the 3-cm diameter circular irradiation
field. In the groups treated with radiation only, tumors with a diameter of 6 mm
were irradiated. In the groups treated with anti-VEGF mAb and radiation,
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anti-VEGF treatment was initiated at a tumor size of 6 mm, and the single
radiation dose was given 24 h after the sixth antibody injection.
Tumors were exposed to single doses under oxygenated (normal blood
flow) or hypoxic (clamped tumors) conditions. In the latter case, a clamp was
placed across the base of the tumor-bearing leg to occlude the tumor blood
flow for 2 min before, and then during, irradiation. The mice were anesthetized
with pentobarbital (50 mg/kg body weight i.p.) before clamping. The mice that
were irradiated under oxygenated conditions were not anesthetized.
Tumor Volume. Tumor diameters in control and treated groups were
measured every 2 days with a caliper. All experimental animals were observed
on a daily basis, and tumor sizes were measured every other day. Tumor
volume was calculated as V 5 ab2/2, where a and b are the long and the short
axes, respectively. Mice were sacrificed with an i.p. injection of pentobarbital
(200 mg/kg body weight) once the tumor reached 12 mm in diameter.
pO2 Measurements. Oxygen measurements were performed in tumors
using a polarographic pO2 histograph (Eppendorf, Hamburg, Germany). The
pO2 was measured once, 24 h after the sixth injection of anti-VEGF mAb. pO2
was also measured in size-matched untreated tumors. The mice were anesthe-
tized with ketamine/xylazine (100/10 mg/kg body weight) and placed on a
heating pad to maintain the body temperature at 37°C. The skin overlying the
tumor was cut and the cathode was placed through the cut to the surface of the
tumor. The electrode was advanced automatically through the tumor, each
forward step followed by a short backward step to reduce artifacts in pO2
measurements from compression of the tissue by the electrode. pO2 measure-
ments were taken in four tumor regions, and 40–50 measurements were taken
in each tumor. The pO2 values represent the median of eight mice per group.
IFP Measurements. The wick-in-needle technique was used to measure
IFP as described previously (19). IFP was measured in two locations in the
center of s.c. tumors, 24 h after the sixth injection of anti-VEGF mAb. Because
the IFP increases with tumor size, IFP was measured in untreated tumors that
were size-matched with the volume of antibody-treated tumors.
Immunohistochemistry. After the mice were killed, tumors were imme-
diately excised and placed in neutral-buffered formalin. The tumors were
embedded in paraffin blocks from which 5 mm sections were cut. The degree
of apoptosis was evaluated using Apop-Tag peroxidase kit (Oncor, Gaithers-
burg, MD) according to the manufacturer’s recommendations. The apoptotic
index was calculated as the percentage of positive nuclei—defined as stained
with peroxidase combined with the presence of a nuclear halo or apoptotic
bodies—observed in a minimum of 400 cells per histological section at a final
magnification of 31240.
To estimate vessel density, tumor sections were incubated overnight at 4°C
with rat antimouse CD31 (PharMingen, San Diego, CA) at a dilution of 1:30.
Visualization of the antigen-antibody reaction was carried out using the Vec-
tastain Elite ABC kit (Vector Laboratories, Burlingame, CA) according to the
recommendations of the manufacturer. Vessel density was determined by
counting the stained vessels in fields of 0.071 mm2 at a final magnification of
3620. A number of 10 to 23 fields per histological section were included in the
analysis.
Western Analysis. Tissue samples were homogenized with lysis buffer
containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1.0% Triton X-100, 10%
NP40, 2 mM EDTA and protease inhibitor cocktail (Complete Mini EDTA-
free, Boehringer Mannheim). 100 mg protein of each lysate were loaded into
12% SDS-PAGE gel, separated, and transferred onto the nitrocellulose mem-
brane. One hundred ng of human recombinant VEGF protein was loaded as
positive control. The membranes were subjected to immunoblotting with rabbit
antimurine VEGF antibody, which was provided by Dr. Donald Senger of Beth
Israel Deaconess Hospital (Boston, MA). The antibody cross-reacts with
human VEGF. Immunodetections were carried out using Western blot chemi-
luminescence reagent (New England Nuclear Life Science Products, Boston,
MA).
Statistical Analysis. The TGD calculations were based on the median time
in days for tumors to grow from 100 to 500 mm3. Some tumors did not reach
500 mm3 during the experiment because either the experiment was interrupted
before the tumors reached 500 mm3 or the tumors regressed. In these cases, the
duration of experiment was used as a censored measure of time to reach 500
mm3. Median times to grow from 100 to 500 mm3 were estimated with
Kaplan-Meier curves. TGD attributable to antibody was estimated as a differ-
ence of such medians in groups treated with anti-VEGF mAb and in corre-
sponding controls (untreated tumors, radiation-treated tumors). The SEs of the
medians and of their differences were obtained with bootstrap methods (20).
We used the log-rank test for statistical comparisons of times to grow from 100
to 500 mm3. Differences in apoptosis, vascular density, IFP, and pO2 between
anti-VEGF mAb and control groups were tested with Student’s t test and
ANOVA for normally distributed data, and with Mann-Whitney U test other-
wise.
RESULTS
VEGF Levels in Tumors. The VEGF protein was detected by
Western analysis in both U87 and LS174T tumors. VEGF levels were
higher in U87 than in LS174T tumors (Fig. 1).
Anti-VEGF mAb Inhibits Tumor Growth. The growth of
LS174T and U87 tumors was progressive for observations up to tumor
volumes of 900-1000 mm3 (Fig. 2a). Anti-VEGF mAb retarded the
growth of both U87 and LS174T, with a significantly greater effect on
the growth of U87 (Table 1). The median TGD induced by the
anti-VEGF mAb was 12 and 22 days for LS174T and U87, respec-
tively. Furthermore, there were larger variations in times to grow to
900 mm3 for U87 tumors. In some U87 tumors the growth retardation
during the 11 days of anti-VEGF mAb treatment was followed at
irregular intervals by periods of several days without growth (Fig. 2a).
Anti-VEGF mAb Reduces Tumor Vessel Density. In both
LS174T and U87 tumors, 24 h after the first anti-VEGF treatment,
microvessel density decreased significantly by 36 and 60%, respec-
tively (Fig. 3a). The microvessel density after the third or sixth
injection of anti-VEGF mAb was still significantly lower as compared
with control tumors.
Induction of Neoplastic Cell Apoptosis by Anti-VEGF mAb.
Concomitant with the decrease in microvessel density, apoptosis was
increased in U87 and LS174T. Compared with controls, apoptosis was
significantly increased in LS174T 24 h after the first and third injec-
tion of anti-VEGF mAb (Fig. 3b). However, after six antibody injec-
tions, the percentage of apoptotic cells was similar to control values.
In U87, the increase in apoptosis was not significant.
Anti-VEGF mAb Reduces IFP. On the basis of the finding that
anti-VEGF reduces tumor vascular permeability and modifies the
architecture of tumor vessels (17), we hypothesized that anti-VEGF
treatment would reduce IFP. The mean IFP of LS174T and U87
dropped by 73 and 74%, respectively (Table 2). Some of the IFP
values, especially in U87 were close to 0 mm Hg, thus comparable
with the IFP in normal tissues. In four of eight treated U87 tumors,
IFP varied between 1.0 and 3.0 mm Hg.
Differential Effect of Anti-VEGF mAb on pO2. The modifica-
tions in tumor vascular density suggest that anti-VEGF mAb could
modify tumor blood flow and pO2. Anti-VEGF mAb increased the
median pO2 in U87 and significantly reduced the frequency of pO2
values below 5 mm Hg (Table 2; Fig. 4a). In LS174T, the antibody
did not change the median pO2, and the decrease in frequency of pO2
values below 5 mm Hg was not significant (Table 2; Fig. 4b).
Anti-VEGF mAb Improves Radiation Response under Hypoxic
and Normoxic Conditions. In comparison with radiation alone, the
combination of anti-VEGF mAb and radiation increased the time for
U87 and LS174T to grow from 100 to 500 mm3 (Fig. 2, b and c; Table
Fig. 1. Western blots of VEGF levels in LS174T and U87 tumors. The quantity of
VEGF protein is higher in U87 than in LS174T. Each lane, a different tumor; recombinant
human VEGF (rh VEGF), control lane.
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1). In most of the U87 tumors, the initial growth delay induced by
radiation was followed by a steady and rapid growth phase. However,
in U87 for both oxic (20 and 30 Gy) and hypoxic (40 Gy) conditions,
anti-VEGF mAb plus radiation interrupted the growth or induced a
steady regression of 10–43% of the tumors (Fig. 2c). In contrast,
radiation alone (30 Gy oxic) induced the regression of only one U87
tumor. The combination of anti-VEGF mAb and radiation was sig-
nificantly less effective in LS174T than in U87 tumors, as shown by
the time that it took to grow from 100 to 500 mm3 and the estimation
of the TGD induced by the antibody (Fig. 5; Table 1).
Radiation alone delayed tumor growth in a dose-dependent manner;
the growth delay was, as expected, less for radiation under hypoxic
than that under aerobic conditions. Except for the significant TGD
between 30 and 40 Gy hypoxic in LS174T tumors, the TGD induced
Fig. 2. Effect of anti-VEGF mAb and the combination of radiation and anti-VEGF mAb
on the growth of U87 and LS174T tumors. In A, the growth of both tumors was significantly
inhibited by anti-VEGF mAb. B and C, effect of radiation or combined anti-VEGF mAb and
radiation under oxic (Oxic) or hypoxic (Hypoxic) conditions on the growth of LS174T (B) and
U87 (C) tumors. In both U87 and LS174T, there was a greater inhibition of tumor growth
induced by the combination of radiation and anti-VEGF mAb as compared with radiation
alone.
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by the combined modality treatment was independent of radiation
dose and tissue oxygenation at irradiation (Fig. 5). In LS174T, the
combination of radiation (40 Gy hypoxic) and antibody induced a
TGD that was greater than additive. At all other radiation doses, the
effect was at best additive. In U87, at all radiation doses and for both
aerobic and clamp hypoxia conditions, the TGD induced by the
anti-VEGF mAb was greater than additive (Fig. 5). For U87, it was
possible to calculate the TGD based on the time after radiation for the
tumors to triple in size. The TGD calculations based on a 3-fold
increase in tumor size (data not shown) or the time for the tumors to
grow from 100 to 500 mm3 gave comparable results.
DISCUSSION
Vascular and Physiological Response to Anti-VEGF mAb.
Within 24 h of the initiation of anti-VEGF treatment there was a
significant decrease in vessel density in U87 and LS174T tumors (Fig.
3a). Previous studies have also shown that the tumor vasculature
regressed rapidly after VEGF down-regulation (21, 22). The reduction
in tumor VEGF levels leads to endothelial cell detachment and apo-
ptosis (21, 22). After VEGF withdrawal, Benjamin and Keshet (21)
found that the marked decrease in the vessels of C6 glioma was
associated with hemorrhage. In contrast, we found no evidence of
hemorrhage. The reduction in tumor IFP is consistent with the de-
crease in vascular permeability after treatment with anti-VEGF mAb
or VEGF down-regulation (11, 17). Variations in vascular response
after VEGF withdrawal or anti-VEGF mAb treatment could be attrib-
utable to differences in the tumor levels of active VEGF, other
survival factors for endothelial cells or the presence of periendothelial
cells (e.g., pericytes). Benjamin et al. (23) have recently shown that
tumor vessels devoid of periendothelial cells regress after the down-
regulation of VEGF levels in the C6 glioma.
Fig. 3. Effect of anti-VEGF mAb on microvessel density (upper panel) and the
apoptotic index (lower panel) in LS174T and U87 tumors. Microvessel density and the
apoptotic index were quantified on histological sections of tumors that were resected 24 h
after the first (T1), third (T3), and sixth (T6) injection of anti-VEGF mAb. There was a
significant decrease in microvessel density (p) at all of the time points studied. The
apoptotic index increased significantly after T1 and T3 in LS174T tumors (p) and returned
to control values after T6. In U87, the increase in apoptosis was not significant. Data
points, the mean 6 SD.
Fig. 4. Histograms of pO2 values in U87 and LS174T tumors. White and black bars,
the pO2 data in the control and anti-VEGF mAb groups, respectively. In U87, the
anti-VEGF mAb induced a shift to the right of the pO2 values as well as a significant
decrease of the pO2 values below 5 and 10 mm Hg. In LS174T, the shift to the right of
the pO2 was small, and there was no significant decrease of the pO2 values below 5 or 10
mm Hg.
Table 1 Effect of the combination of the anti-VEGF mAb and radiation on tumor
growth parameters
Tumor
normoxic/hypoxic
Radiation
dose (Gy)
Time to grow from 100
to 500 mm3
TGD PNo antibody antibody
LS174T 0 11 6 1.0a 23 6 1.4 12 6 1.8 0.00002
Normoxic 20 23 6 1.7 33 6 8.7 10 6 8.8 0.0008
30 35 6 10.2 51 6 4.1 16 6 11.0 0.9
Hypoxic 30 19 6 1.4 35 6 8.1 16 6 8.2 0.025
40 25 6 3.0 55 6 8.8 30 6 9.3 0.07
U87 0 13 6 1.0 35 6 5.0 22 6 5.1 0.00001
Normoxic 20 26 6 2.7 67 6 8.7 41 6 9.1 0.0005
30 35 6 4.2 89 6 7.2 54 6 8.4 0.002
Hypoxic 30 23 6 1.2 63 6 4.2 40 6 4.3 0.00005
40 31 6 3.1 77 6 7.4 46 6 8.1 0.002
a Median 6 SE.
Table 2 Effect of anti-VEGF mAb on mean IFP and median pO2
Tx U87 LS174T
IFP (mm Hg) Control 12.0 6 3.0 13.5 6 4.0
Anti-VEGF mAb 3.0 6 1.5a 3.5 6 1.0a
pO2 (mm Hg) Control 14 (8.0–18.5) 12.0 (8–16)
Anti-VEGF mAb 20.5 (13–24)a 14.0 (11–14.5)
a P , 0.05.
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Antiangiogenic agents like squalamine, and TNP-470 combined
with minocycline can reduce the degree of hypoxia in tumors (1, 9).
Interestingly, in U87 the vessel regression induced by the anti-VEGF
mAb was associated with an increase in median pO2 and a decrease in
hypoxic values below 5.0 mm Hg. The increase in pO2 despite a
decrease in vascular density suggests that it is the quality of the
vascular organization and not just the quantity of vessels that deter-
mines the oxygen levels in a tumor. The improvement in tumor
oxygenation could also be explained by a decrease in the number of
tumor and endothelial cells consuming oxygen. Oxygen consumption
by endothelial cells is significant, and it most likely influences the pO2
values in tissues (24, 25).
Elevated IFP is a hallmark of solid tumors (26). Anti-VEGF mAb
reduced IFP from 12.0 to 3.0 mm Hg in U87 and from 13.5 to 3.5 mm
Hg in LS174T, thus showing that VEGF is an important molecule
responsible for the interstitial hypertension in solid tumors. Further-
more, especially in some anti-VEGF-treated U87 tumors, the IFP was
reduced to 1–2 mm Hg, which is comparable with the pressure in the
subcutis and other normal tissues, which varies between 0 and 22.0
mm Hg (27). Two vascular factors contribute to interstitial hyperten-
sion in solid tumors: the high permeability of tumor vessels and the
tortuous nature including compression (reduction in vessel diameter)
of vessels. The high vascular permeability and hydraulic conductivity
of tumor vessels favor the equilibration of the MVP and IFP (28). The
tortuous architecture of the vasculature and the vessel compression by
tumor cells increase the vascular resistance and thus the MVP (29).
Treatment with anti-VEGF mAb decreases vascular permeability (17)
and could directly lower IFP. Furthermore, the loss of endothelial
cells would reduce the tortuosity of vessels or eliminate vessels
altogether. This modification in vascular architecture would reduce
flow resistance and, hence, lower both MVP and IFP. Thus, VEGF
contributes significantly to the high IFP in solid tumors, and normal-
ization in vascular permeability and architecture is probably respon-
sible for the lower IFP induced by the anti-VEGF mAb.
Antitumoral Effects of Anti-VEGF mAb. Similar to other stud-
ies, we found that the anti-VEGF mAb retards tumor growth and has
differential effects dependent on the tumor type (13–16). Anti-VEGF
mAb induced a TGD of only 6 days in a human sarcoma (data not
shown), whereas the growth delays in LS174T and U87 were of 12
and 22 days, respectively. The differential tumor response to anti-
VEGF mAb could be attributable to the relative levels of host (mu-
rine) versus human VEGF, the absolute levels of VEGF, or other
growth factors that stimulate angiogenesis. The mAb A.4.6.1 binds
and neutralizes human VEGF and does not block murine VEGF.
Fukumura et al. (30) have recently shown that host (mouse) stromal
cells in human tumor xenografts can be a source of VEGF. The
expression of VEGF varies from one tumor type to another. In accord
with the finding that the levels of VEGF protein were higher in U87
than in LS174T tumors (Fig. 1), the anti-VEGF mAb did effect a
greater TGD in U87 as compared with LS174T. However, other
reports have found no correlation between the levels of VEGF pro-
duced in vitro or in vivo and the antitumor response induced by the
antihuman VEGF mAb MV833 (13, 15). Potential differences in
antibody specificity or affinity could also affect antitumor response. In
the present study, the mAb 4.6.1 against human-VEGF induced a
significant delay in the growth of s.c. U87 tumors in nude mice. In
contrast, mAb 293 against human VEGF did not inhibit the growth of
U87 that was also implanted s.c. in nude mice (4).
In comparison with LS174T, the greater reduction in vascular
density in U87 could be responsible for the larger TGD in that tumor.
Tumor volume doubling times were comparable in untreated U87 (4.5
days) and LS174T (4.0 days), whereas the vessel density was of 27
and 15 vessels/mm2, respectively. Vessel loss induced by the anti-
VEGF mAb was 2.5 fold greater in U87 as compared with LS174T.
Modifications in tumor cell proliferation or apoptosis induced by
antiangiogenic agents could also explain the TGD induced by the
anti-VEGF mAb. The in vitro proliferation of U87 tumor cells is not
modified by the anti-VEGF mAb 4.6.1 (17). Yoshigi et al. (31) have
shown that the in vivo inhibition of the VEGF signaling pathway in
endothelial cells is associated with an increase in tumor cell apoptosis;
however, the number of proliferating tumor cells was not modified
(31). Increases in tumor cell apoptosis are also induced by various
antiangiogenic agents (5–7, 32) including anti-VEGF mAb treatment
and deletion of the VEGF gene in ras-transformed fibroblasts (8, 11).
The small increase in apoptosis in U87 and LS174T probably plays a
minor role in the inhibition of growth by the anti-VEGF mAb.
Furthermore, the greater induction of apoptosis in LS174T was asso-
ciated with a smaller antitumor response as compared with U87. We
did not quantify necrosis; however, the examination of histological
slides did not reveal obvious differences in necrosis between control
and anti-VEGF mAb-treated tumors. Thus, based on the present
results, the inhibition of angiogenesis is probably the dominant factor
responsible for the TGD induced by the anti-VEGF mAb in both U87
and LS174T tumors.
Combination of Radiation and Anti-VEGF Improves Tumor
Response. One of the aims of the present study was to determine
whether the increased TGD induced by the combination of anti-VEGF
and radiation was dependent on the oxygenation status at the time of
radiation. Similar to previous studies with other antiangiogenic agents
(1, 9), the anti-VEGF mAb treatment reduced the hypoxia in U87
tumors. However, the TGD induced by the combination treatment was
found to be essentially independent of tumor oxygenation. At the
radiation dose of 30 Gy for both oxic and hypoxic conditions, the
anti-VEGF mAb induced a TGD of 16 days in LS174T (Fig. 5).
Similarly, in U87 tumors, there was no significant difference in TGD
between aerobic and clamp hypoxia conditions. The increased TGD at
40 Gy hypoxic in LS174T also supports the interpretation that the
oxygen level in a tumor is probably not the major cause of the
increased radioresponse induced by the anti-VEGF mAb.
In U87, the combination of anti-VEGF mAb and radiation induced
a TGD that was greater than additive. This enhancement in TGD
could be attributable to vessel loss resulting from both antibody and
Fig. 5. TGD induced by the anti-VEGF mAb in tumors treated either with anti-VEGF
alone or with the combination of radiation and anti-VEGF mAb. In both U87 and LS174T
tumors, the TGD resulting from the anti-VEGF mAb was generally independent of the
radiation dose or the oxygen levels in the tumor at the time of radiation. In LS174T treated
under hypoxic conditions, a significant difference in TGD was found between 30 and 40
Gy (p). In U87 tumors and in LS174T, (only at a dose of 40 Gy under clamped hypoxia)
the antibody induced a TGD that was greater than additive. Data points, the median 6 SE.
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radiation treatment. Radiation doses of 16–21 Gy resulted in the loss
of 50% of the vessels in a human melanoma implanted in nude mice
(33). Furthermore, the cytotoxic effects of radiation could be en-
hanced by the inhibition of VEGF in the tumor at the time of radiation.
VEGF protects against radiation-induced endothelial cell killing and
the addition of anti-VEGF mAb to endothelial cells in vitro increased
the cytotoxic effects of radiation (4).
In conclusion, our results show that the anti-VEGF mAb signifi-
cantly reduces tumor IFP and hypoxia. The improvement in tumor
oxygenation was associated with a major decrease in vascular density
in U87. The efficacy of the combined radiation and anti-VEGF mAb
treatment was tumor-dependent. The TGD induced by the combina-
tion treatment was greater than additive in U87, whereas in LS174T
(except for 40 the Gy hypoxic group) the TGD was additive. In both
U87 and LS174T, the enhanced TGD resulting from the anti-VEGF
mAb was independent of the radiation dose and tumor oxygenation at
the time of irradiation. The insignificant difference in TGD when
radiation is given under oxic and hypoxic conditions suggests that the
reduced hypoxia in U87 plays a minor role in the antitumor effect of
the anti-VEGF mAb and radiation combination. The reduced vascular
density induced by the anti-VEGF mAb is probably a significant
factor that enhances the radiation effect under both oxic and hypoxic
conditions.
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